Amgen Puts Evenity Filing Back On Track With TIMI Cardiovascular Risk Review
Executive Summary
As Amgen’s main hope for extending its bone health franchise, romosozumab faces a second review at the FDA with a fuller dataset and an external analysis of cardiovascular risk.
You may also be interested in...
Amgen's Evenity Clears US FDA With Preferred Indication, Black Box Warning
Osteoporosis treatment romosozumab-aqqg indicated for postmenopausal women at high risk for fracture; advisory committee appears to have help persuade FDA that a black box would be sufficient to manage cardiovascular risk rather than a narrower indication.
Japan Approvals Include World Firsts For Romosozumab, Spinal Injury Cell Therapy
The latest group of new product approvals in Japan includes the first marketing clearances worldwide for fracture-reducing osteoporosis antibody romosozumab and a stem cell-based therapy for spinal cord injury, as well as two new Daiichi drugs and Pfizer's lung cancer therapy dacomitinib.
Amgen's Evenity Faces CV Safety Gauntlet At US FDA Advisory Cmte.
Narrower indication and a boxed warning for Amgen's osteoporosis drug romosozumab might be sufficient to permit approval.